1. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–7.

   Article PubMed CAS  Google Scholar 

2. Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med. 2007;4:1056–69.

   Article PubMed  Google Scholar 

3. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48:955–8.

   Article PubMed CAS  Google Scholar 

4. Kaler LW, Neaves WB. The androgen status of aging male rats. Endocrinology. 1981;108:712–9.

   Article PubMed CAS  Google Scholar 

5. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557–62.

   Article PubMed CAS  Google Scholar 

6. O’Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf). 1985;23:527–38.

   Article  Google Scholar 

7. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case–control study. Am J Med Sci. 1992;304:4–8.

   Article PubMed CAS  Google Scholar 

8. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787–91.

   Article PubMed CAS  Google Scholar 

9. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601–7.

   PubMed CAS  Google Scholar 

10. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the telecom study. J Clin Endocrinol Metab. 1997;82:682–5.

    Article PubMed CAS  Google Scholar 

11. Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int. 2005;96:48–53.

    Article PubMed CAS  Google Scholar 

12. Slabbekoorn D, van Goozen SH, Megens J, Gooren LJ, Cohen-Kettenis PT. Activating effects of cross-sex hormones on cognitive functioning: a study of short-term and long-term hormone effects in transsexuals. Psychoneuroendocrinology. 1999;24:423–47.

    Article PubMed CAS  Google Scholar 

13. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162–7.

    Article PubMed  Google Scholar 

14. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.

    Article PubMed CAS  Google Scholar 

15. Morales A, Heaton JP, Carson 3rd CC. Andropause: a misnomer for a true clinical entity. J Urol. 2000;163:705–12.

    Article PubMed CAS  Google Scholar 

16. Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol. 2000;161:73–88.

    Article PubMed CAS  Google Scholar 

17. Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metab. 2011;25:251–70.

    Article PubMed CAS  Google Scholar 

18. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–7.

    Article PubMed  Google Scholar 

19. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–92.

    Article PubMed CAS  Google Scholar 

20. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab. 1995;80:3546–52.

    Article PubMed CAS  Google Scholar 

21. World Health Organisation (WHO). Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.Fertil Steril. 1996;65:821–9.

    Google Scholar 

22. Shabsigh A, Kang Y, Shabsign R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med. 2005;2:716–21.

    Article PubMed CAS  Google Scholar 

23. Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf). 2002;56:637–41.

    Article CAS  Google Scholar 

24. de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod. 2009;24:425–8.

    Article PubMed  Google Scholar 

25. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf). 2010;72:731–7.

    Article CAS  Google Scholar 

26. Ko EY, Siddiqi K, Brannigan RE, Sabanegh Jr ES. Empirical medical therapy for idiopathic male infertility: a survey of the American urological association. J Urol. 2012;187:973–8.

    Article PubMed  Google Scholar 

27. Schiff JD, Ramirez ML, Bar-Chama N. Medical and surgical management male infertility. Endocrinol Metab Clin North Am. 2007;36:313–31.

    Article PubMed  Google Scholar 

28. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe Jr L. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6:212–24.

    Article PubMed CAS  Google Scholar 

29. Tenover JS, Bremner WJ. The effects of normal aging on the response of the pituitary-gonadal axis to chronic clomiphene administration in men. J Androl. 1991;12:258–63.

    PubMed CAS  Google Scholar 

30. Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men.BJU Int. 2012;110(4):573–8.

    Google Scholar 

31. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15:156–65.

    Article PubMed CAS  Google Scholar 

32. Ioannidou-Kadis S, Wright PJ, Neely RD, Quinton R. Complete reversal of adult-onset isolated hypogonadotropic hypogonadism with clomiphene citrate. Fertil Steril. 2006;86:1513.e5–9.

    Article  Google Scholar 

33. Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010;7:269–76.

    Article PubMed CAS  Google Scholar 

34. Ribeiro RS, Abucham J. Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas. Arq Bras Endocrinol Metabol. 2011;55:266–71.

    Article PubMed  Google Scholar 

35. Ribeiro RS, Abucham J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol. 2009;161:163–9.

    Article PubMed CAS  Google Scholar 

36. Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs. 2009;18:1947–55.

    Article PubMed CAS  Google Scholar 

37. Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs. 2009;12:109–19.

    PubMed CAS  Google Scholar 

38. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol. 2002;167:624–9.

    Article PubMed CAS  Google Scholar 

39. Holbrook JM, Cohen PG. Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation. South Med J. 2003;96:544–7.

    Article PubMed  Google Scholar 

40. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.Clin Endocrinol (Oxf). 2009;70(1):116–23.

    Google Scholar 

41. Herzog AG, Farina EL, Drislane FW, et al. A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism. Epilepsy Behav. 2010;17:264–71.

    Article PubMed  Google Scholar 

42. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89:1174–80.

    Article PubMed CAS  Google Scholar 

43. Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf). 2005;62:228–35.

    Article CAS  Google Scholar 

44. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005;16:1487–94.

    Article PubMed CAS  Google Scholar 

45. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94:4785–92.

    Article PubMed CAS  Google Scholar 

46. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. 2009;92:594–604.

    Article PubMed CAS  Google Scholar 

Download references